We have selected gambogic acid as a promising therapeutic candidate for the inhibition of both IL-1β and TNF secretion, due to the reduction in caspase-1 and NF-κB activation, and consequently for the treatment of arthritis. The gene discussed is IL1B; the disease is arthritic joint disease.